Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Trastuzumab in a Patient with Metastatic Salivary Duct Carcinoma : A Case Report

트라스투주맙 치료에 반응을 보인 HER2/neu 양성 전이성 타액관 암종 1예

  • Kong, Bong Han (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Lee, Jieun (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Choi, Sang-Su (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Park, Jinhee (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kim, Yeon Shil (Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kim, Min-Sik (Department of Otorhinolaryngology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Lee, Youn-Soo (Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Lee, Ji-Yeon (International Health Care Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Hong, Sook Hee (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kang, Jin Hyoung (Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine)
  • 공봉한 (가톨릭대학교 의과대학 내과학교실) ;
  • 이지은 (가톨릭대학교 의과대학 내과학교실) ;
  • 최상수 (가톨릭대학교 의과대학 내과학교실) ;
  • 박진희 (가톨릭대학교 의과대학 내과학교실) ;
  • 김연실 (가톨릭대학교 의과대학 방사선종양학교실) ;
  • 김민식 (가톨릭대학교 의과대학 이비인후과학교실) ;
  • 이연수 (가톨릭대학교 의과대학 병리과학교실) ;
  • 이지연 (가톨릭대학교 의과대학 국제진료센터) ;
  • 홍숙희 (가톨릭대학교 의과대학 내과학교실) ;
  • 강진형 (가톨릭대학교 의과대학 내과학교실)
  • Received : 2014.09.12
  • Accepted : 2014.10.02
  • Published : 2014.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Salivary duct carcinoma(SDC) is rare malignancy, accounting for approximately 1-3% of all malignant salivary gland tumors. Systemic chemotherapy has been used for stage IV SDC, but there is no consensus on the standard treatment. SDC is histologically similar to ductal carcinoma of breast and often overexpress HER2/neu, hence HER2/neu targeted therapy could be one of treatment options. A 75-year-old Arabian man was diagnosed as SDC of right parotid gland with extensive metastases. He received oral 5-FU as palliative chemotherapy, but he was intolerable to oral chemotherapy due to severe oral mucositis. Considering immunohistochemical stain of tumor tissue showing strong positive for HER2/neu, we decided to administer an anti-HER2/neu antibody, trastuzumab. Follow-up CT scans before the third dose of trastuzumab demonstrated remarkable regression of multiple metastases as well as primary tumor. This case suggests that HER2/neu targeted therapy may be a potential therapeutic option for the SDC patient with overexpression of HER2/neu.

Keywords

References

  1. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: A report of 50 cases. Cancer. 2005;103:2526-2533. https://doi.org/10.1002/cncr.21116
  2. Pfister DG, Ang K-K, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. NCCN clinical practice guidelines in oncology, Head and neck cancers, version 2. 2013.
  3. Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003;1:226-228.
  4. Clauditz TS, Reiff M, Gravert L, Gnoss A, Tsourlakis MC, Munscher A, et al. Human epidermal growth factor receptor 2(HER2) in salivary gland carcinomas. Pathology. 2011;43(5):459-464. https://doi.org/10.1097/PAT.0b013e3283484a60
  5. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, et al. HER2 expression in salivary gland carcinomas: Dependence on histological subtype. Clin Cancer Res. 2004;10:944-946. https://doi.org/10.1158/1078-0432.CCR-03-0253
  6. Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192:100-105. https://doi.org/10.1007/BF00301495
  7. Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294-300. https://doi.org/10.1634/theoncologist.2012-0369
  8. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009;133:1763-1774.
  9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. https://doi.org/10.1056/NEJM200103153441101
  10. Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008;30:680-683. https://doi.org/10.1002/hed.20714
  11. Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK. Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature. Head Neck. 2013;35(12):372-375. https://doi.org/10.1002/hed.23307